Investigational New Drug CDMO Market (By Product: Small Molecule, Large Molecule; By Service: Contract Development, Contract Manufacturing; By End-use: Pharmaceutical Companies, Biotech Companies, Others (Government, Research Institutes, Academic Institutes, etc.)) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Investigational New Drug CDMO Market, By Product

7.1.  Investigational New Drug CDMO Market, by Product, 2021-2030

7.1.1.    Small Molecule

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Large Molecule

7.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Investigational New Drug CDMO Market, By Service

8.1.  Investigational New Drug CDMO Market, by Service, 2021-2030

8.1.1.    Contract Development

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Contract Manufacturing

8.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Investigational New Drug CDMO Market, By End User

9.1.  Investigational New Drug CDMO Market, by End User, 2021-2030

9.1.1.    Pharmaceutical Companies

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Biotech Companies

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Others (Government, Research Institutes, Academic Institutes, etc.)

9.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Investigational New Drug CDMO Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Product (2017-2030)

10.1.2.  Market Revenue and Forecast, by Service (2017-2030)

10.1.3.  Market Revenue and Forecast, by End User (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Service (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Service (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Product (2017-2030)

10.2.2.  Market Revenue and Forecast, by Service (2017-2030)

10.2.3.  Market Revenue and Forecast, by End User (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Service (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Service (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Service (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Service (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Product (2017-2030)

10.3.2.  Market Revenue and Forecast, by Service (2017-2030)

10.3.3.  Market Revenue and Forecast, by End User (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Service (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Service (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Service (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Service (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Product (2017-2030)

10.4.2.  Market Revenue and Forecast, by Service (2017-2030)

10.4.3.  Market Revenue and Forecast, by End User (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Service (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Service (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Service (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Service (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Product (2017-2030)

10.5.2.  Market Revenue and Forecast, by Service (2017-2030)

10.5.3.  Market Revenue and Forecast, by End User (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Service (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Service (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by End User (2017-2030)

Chapter 11.  Company Profiles

11.1.              Covance Inc.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Charles River Laboratories Inc.

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Cambrex Corporation

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              IQVIA Holdings Inc.

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Syneos Health

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Lonza

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Catalent

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Recipharm AB

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Siegfried Holding AG

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Thermo Fisher Scientific Inc.

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Report Details

  • Report Code:38506
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:September 2021
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers